Strategic partnerships Opportunity: Leverage Bicycle Therapeutics’ radiopharmaceutical and radioconjugate platforms (BRC) for oncology applications in collaboration with radiopharma players, nuclear labs, and healthcare providers seeking novel cancer therapies and diagnostic imaging.

Clinical pipeline leverage Opportunity: Target pharma and biotech sponsors interested in novel targets (Nectin-4, EphA2) and Immuno-Oncology modalities (Bicycle TICA) for co-development or licensing deals, with emphasis on BTC and novel radioconjugates to expand candidate portfolios.

Geographic reach Opportunity: Engage US and UK/EU biopharma partners and contract research organizations to accelerate trials and commercialization, capitalizing on Bicycle Therapeutics’ dual HQ presence and established collaborations with nuclear and academic institutions.

Financing & scalability Opportunity: Present strategic financing or milestone-based partnerships to leverage the company’s strong funding position and ongoing clinical advancement, aligning with potential licensee or co-development deals that require substantial R&D funding.

Technology adoption Opportunity: Position Bicycle’s proprietary bicyclic peptide platform as a differentiator for partners seeking high-affinity, selective targeting; offer technology transfer, collaboration on new targets, or embedded discovery services to expand revenue streams.